Production (Stage)
Spero Therapeutics, Inc.
SPRO
$2.13
-$0.22-9.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -69.76M | -68.57M | 3.51M | 17.46M | 23.40M |
| Total Depreciation and Amortization | 2.00K | 2.00K | 40.00K | 148.00K | 254.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.39M | 8.84M | 9.31M | 14.35M | 14.08M |
| Change in Net Operating Assets | 27.99M | 36.28M | -30.40M | -46.34M | -51.94M |
| Cash from Operations | -33.38M | -23.44M | -17.54M | -14.38M | -14.20M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 1.00K | 221.00K | 221.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 1.00K | 221.00K | 221.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -33.38M | -23.44M | -17.54M | -14.16M | -13.98M |